Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for global professionals · Sunday, September 23, 2018 · 462,759,914 Articles · 3+ Million Readers

Radiodermatitis Market Value to Reach US$421.5 million by the End of 2024: Transparency Market Research

Radiodermatitis Market (Product type - Topical (Corticosteroids, Hydrophilic Creams, and Topical Antibiotics), Oral Medication (Corticosteroids, Oral Analgesics, Antibiotics), and Dressings (Hydrogel, Hydrocolloid, No Sting Barrier Film, Honey Impregnated Gauze, Silicone Coated Dressing (GM-CSF Gauze and Silver Leaf Dressing); By Distribution Channel - Hospital Pharmacy, Retail Pharmacy Store, and Online Store) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Albany – NY, Dec. 14, 2017 (GLOBE NEWSWIRE) -- The global radiodermatitis market is consolidated, with the top five players accounting for a share of just over 47% in 2015. These are 3M Healthcare, Smith & Nephew plc, Molnlycke Health Care, Acelity, and Convatec, Inc. Transparency Market Research finds that success in the radiodermatitis market is dependent on the ability of pharma and medical device companies to develop innovative products that can address unmet consumer needs and also help differentiate the company from its competitors.

Stratpharma AG, for instance, launched the StrateXRT in 2016 – a class 1 wound dressing listed with the US FDA and a medical device registered with the European CE mark. This novel and flexible wound dressing is designed for the prevention as well as treatment of radiation dermatitis.

The opportunity in the global radiodermatitis market was worth US$299.6 mn in 2015 and, registering a CAGR of 3.9% from 2016 to 2024, will be worth US$421.5 mn by 2024.

View Report at https://www.transparencymarketresearch.com/radiodermatitis-market.html

Multichannel Distribution an Effective Approach in Radiodermatitis Market

Topical agents are the most preferred and prescribed products in the radiodermatitis market. Accounting for a share of just under 70% in 2015, the revenue generated by this segment is projected to cross US$300 mn by 2024. The topical segment is anticipated to register a 4.2% CAGR during the forecast period, higher than any other product segment. The oral medication segment holds a negligible share in the global radiodermatitis market and is anticipated to further lose market share by 2024.

By distribution channel, the retail pharmacy store segment led the radiodermatitis market in 2015, closely followed by the online store segment. TMR finds that on the whole, a multichannel approach works increasingly well in the radiodermatitis market owing to the nature of the onset of radiodermatitis, which can occur either during or after radiation therapy.

/EIN News/ -- Request to View Sample Copy of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=2157

Geographically, Asia Pacific led the global radiodermatitis market in 2015, accounting for a share of over 45% that year. This region, along with Latin America, are both anticipated to register a CAGR of 4.0% from 2016 to 2024, emerging as two of the most lucrative markets for radiodermatitis treatment.

Request Radiodermatitis Market Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2157

Innovation in Product Offerings a Key Growth Driver for Radiodermatitis Market

The World Health Organization states that the number of new cancer cases worldwide is projected to rise from 14 million per year in 2012 to 22 million by 2032. Cancer patients are more likely to develop radiation-induced dermatitis owing to frequent radiation treatments. “Unhealthy lifestyle factors, such as obesity and smoking, aggravate the rate of cancer incidence and this will further boost the prevalence as well as market for radiodermatitis,” the author of the study finds.

Request to view table of content @ https://www.transparencymarketresearch.com/report-toc/2157

The global market for radiodermatitis is also fueled by the rising innovation in product offerings. “Companies have been increasingly focused on churning out innovative products in order to fill the gap of unmet needs in the radiodermatitis market,” the lead analyst observes. The painful condition of the patient and poor quality of life has been compelling patients to opt for as many new and different radiodermatitis treatment options as possible and this acts as a driving factor for drug and device manufacturing companies.

Global Radiodermatitis Market Report is available @ US$ 5795

About TMR

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact


Transparency Market Research

Mr Rohit Bhisey
State Tower
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.theglobalhealthnews.com/

Primary Logo

Powered by EIN News